Updates in the management of high-grade glioma

被引:0
作者
David Bradley
Jeremy Rees
机构
[1] The National Hospital for Neurology and Neurosurgery,
来源
Journal of Neurology | 2014年 / 261卷
关键词
Glioblastoma; Oligodendroglioma; Bevacizumab; Temozolomide; PCV;
D O I
暂无
中图分类号
学科分类号
摘要
The management of high-grade glioma (HGG) has evolved significantly over the last decade. Patients are managed in a multidisciplinary team setting in order to ensure their care is guided by the most current evidenced based treatments. The outcome in patients with HGG, while still poor, has improved in terms of both survival and quality of life during illness. This review discusses a number of developments seen in the management of HGG over the last 5 years.
引用
收藏
页码:651 / 654
页数:3
相关论文
共 173 条
[1]  
Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996
[2]  
Mason WP(2009)Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459-466
[3]  
van den Bent MJ(2012)Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol 13 916-926
[4]  
Weller M(2012)Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol 13 707-715
[5]  
Stupp R(2003)Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 401-410
[6]  
Hegi ME(2004)Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184-2191
[7]  
Mason WP(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342
[8]  
van den Bent MJ(2003)A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427-434
[9]  
Malmstrom A(2007)Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666-2676
[10]  
Gronberg BH(2006)Angiogenesis in malignant glioma—a target for antitumor therapy? Crit Rev Oncol Hematol 59 181-193